



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/804,987	03/13/2001	Christian Waeber	M0765/7035 (ERG/MAT)	9309

7590

12/01/2003

Edward R. Gates
c/o Wolf, Greenfield & Sacks, P.C.
Federal Reserve Plaza
600 Atlantic Avenue
Boston, MA 02210-2211

EXAMINER

LI, RUIXIANG

ART UNIT

PAPER NUMBER

1646

#18

DATE MAILED: 12/01/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

Intervi w Summary	Application No.	Applicant(s)	
	09/804,987	WAEBER ET AL.	
	Examiner	Art Unit	
	Ruixiang Li	1646	

All participants (applicant, applicant's representative, PTO personnel):

(1) Ruixiang Li.

(3) Janice Vatland.

(2) Yvonne Eyler.

(4) Maria Trepisan.

Date of Interview: 24 November 2003.

Type: a) ☐ Telephonic b) ☐ Video Conference
c) ☐ Personal [copy given to: 1) ☐ applicant 2) ☐ applicant's representative]

Exhibit shown or demonstration conducted: d) ☐ Yes e) ☒ No.
If Yes, brief description: _____.

Claim(s) discussed: 34, 43, 56, 88-91, 93, 96-99, 101-105, 108-111, 113, 114, 121-131, 134 and 137.

Identification of prior art discussed: Bischoff et al., Br. J. Pharmacol. 130: 1871-1877, 2000; Bischoff et al., Br. J. Pharmacol. 130: 1878-1883, 2000; Ohmori et al., Cardio. Res., 58:170-177, 2003.

Agreement with respect to the claims f) ☐ was reached. g) ☒ was not reached. h) ☐ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: See Continuation Sheet.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.

Ruixiang Li
Examiner's signature, if required

Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments:

The issues related to scope enablement for (i) arteries, (ii) agents that downregulate an EDG receptor signaling, and (iii) EDG receptors, were discussed. The Examiner maintained that the specification does not enable a method of increasing vasodilation or inhibition of vasoconstriction in any arteries comprising any agents that downregulate any EDG receptor signaling.

The issue related to written description regarding "a neuroprotective agent" was also discussed. Applicants would consider submitting an amendment either to narrow the scope of the invention or to substantiate their arguments.